Argos Therapeutics Company Profile (NASDAQ:ARGS)

About Argos Therapeutics (NASDAQ:ARGS)

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARGS
  • CUSIP: N/A
  • Web: www.argostherapeutics.com
Capitalization:
  • Market Cap: $9.62 million
  • Outstanding Shares: 54,974,000
Average Prices:
  • 50 Day Moving Avg: $0.21
  • 200 Day Moving Avg: $0.42
  • 52 Week Range: $0.17 - $5.68
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $485,347.00
  • Price / Sales: 20.39
  • Book Value: ($0.49) per share
  • Price / Book: -0.37
Profitability:
  • EBIDTA: ($44,470,000.00)
  • Net Margins: -12,391.15%
  • Return on Equity: -1,532.49%
  • Return on Assets: -92.03%
Debt:
  • Debt-to-Equity Ratio: -1.20%
  • Current Ratio: 1.51%
  • Quick Ratio: 1.51%
Misc:
  • Average Volume: 2.49 million shs.
  • Beta: 1.38
  • Short Ratio: 0.84
 

Frequently Asked Questions for Argos Therapeutics (NASDAQ:ARGS)

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics, Inc. (NASDAQ:ARGS) posted its earnings results on Wednesday, August, 9th. The company reported ($0.21) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.02. The business earned $0.07 million during the quarter, compared to analyst estimates of $0.10 million. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%. View Argos Therapeutics' Earnings History.

Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?

3 brokerages have issued 12 month price targets for Argos Therapeutics' shares. Their forecasts range from $1.20 to $10.00. On average, they anticipate Argos Therapeutics' share price to reach $4.13 in the next twelve months. View Analyst Ratings for Argos Therapeutics.

What are analysts saying about Argos Therapeutics stock?

Here are some recent quotes from research analysts about Argos Therapeutics stock:

  • 1. According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (8/14/2017)
  • 2. Stifel Nicolaus analysts commented, "Argos reported 4Q16 numbers that included a net loss of $15.4 million and a cash & cash equivalents balance of $53.0 million. This is a time of transition for the company as last month, the IDMC recommended Argos discontinue their Phase III trial of AGS-003 in mRCC (ADAPT) based on futility. The trial is still ongoing while the company is reviewing preliminary data and determining the path forward. In the meantime, the company is reducing its workforce in an effort to conserve cash. However, since quarter's end, one of the company's lenders called its outstanding $23.1 million loan so Argos' current cash balance is closer to about $30 million. As a result of the reduced cash position, we are decreasing our target price from $1.40 to $1.20." (3/17/2017)
  • 3. FBR & Co analysts commented, "On the morning of February 22, Argos Therapeutics announced that the Independent Data Monitoring Committee (IDMC) recommended that the company’s pivotal Phase III ADAPT clinical trial of rocapuldencel-T (AGS-003) in combination with sunitinib (standard therapy) for the treatment of metastatic renal cell carcinoma (mRCC) be discontinued for futility based on its planned interim data analysis. The IDMC came to a conclusion that the study was unlikely to demonstrate a statistically significant improvement in overall survival (OS) in the combination treatment arm of rocapuldencel-T and sunitinib. The company is in the process of analyzing preliminary data from the trial, and its next steps involve discussing the data with the FDA." (2/23/2017)
  • 4. Needham & Company LLC analysts commented, "Argos announced that the pivotal Phase III ADAPT trial of rocapuldencel-T (AGS-003) in renal cell carcinoma (RCC) reached futility at a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has recommended discontinuation of the trial. Argos plans to leave the trial open pending further data review and FDA discussion, however, we view the likelihood of approval in RCC, our main valuation driver, as too uncertain. We are downgrading shares to Neutral." (2/22/2017)

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:

  • Hubert Birner Ph.D., Independent Chairman of the Board
  • Jeffrey D. Abbey, President, Chief Executive Officer, Director
  • Richard Katz M.D., Chief Financial Officer, Vice President
  • Lori R. Harrelson, Vice President - Finance
  • John D. Menditto, Vice President - Corporate Communications & Investor Relations
  • Douglas C. Plessinger, Vice President - Medical and Clinical Affairs
  • Charles A. Nicolette Ph.D., Vice President - Research & Development, Chief Scientific Officer
  • Robert F. Carey, Director
  • Igor Krol, Director
  • Irackly Mtibelishvily, Director

Who owns Argos Therapeutics stock?

Argos Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include PHARMSTANDARD INTERNATIONAL S.A. (39.90%) and Vanguard Group Inc. (1.89%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jeffrey D Abbey and Joan Winterbottom. View Institutional Ownership Trends for Argos Therapeutics.

Who sold Argos Therapeutics stock? Who is selling Argos Therapeutics stock?

Argos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Argos Therapeutics.

How do I buy Argos Therapeutics stock?

Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of Argos Therapeutics stock can currently be purchased for approximately $0.18.


MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.13 (2,196.30% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$2.00 -> $1.20HighView Rating Details
3/17/2017Stifel NicolausLower Price TargetHold$1.20HighView Rating Details
2/22/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
2/22/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $12.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Earnings History by Quarter for Argos Therapeutics (NASDAQ ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.23)($0.21)$0.10 million$0.07 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.35)($0.32)$0.35 million$0.15 millionViewN/AView Earnings Details
8/10/2016Q2($0.43)($0.48)$0.16 million$0.49 millionViewListenView Earnings Details
5/12/2016Q1($0.56)($0.57)$0.10 million$0.15 millionViewListenView Earnings Details
3/29/2016Q4($0.88)($0.84)$1.12 million$0.07 millionViewListenView Earnings Details
11/16/2015Q315($0.92)($0.97)$0.12 million$0.16 millionViewListenView Earnings Details
8/12/2015Q215($0.80)($0.95)$1.32 million$0.11 millionViewListenView Earnings Details
5/14/2015Q115($0.81)($0.89)$0.40 million$0.18 millionViewListenView Earnings Details
3/30/2015Q314($0.78)($0.83)$0.62 million$0.30 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.65)($0.77)$0.80 million$0.40 millionViewN/AView Earnings Details
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($0.54)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014Q4 2013($3.42)($36.19)$2.60 million$0.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.32)($0.32)($0.32)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Argos Therapeutics (NASDAQ:ARGS)
Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 27.91%
Insider Trades by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Insider Trades by Quarter for Argos Therapeutics (NASDAQ:ARGS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Argos Therapeutics (NASDAQ:ARGS)
Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
Source:
DateHeadline
seekingalpha.com logoArgos Therapeutics (ARGS) Interim Analysis Of The Phase 3 Adapt Trial Evaluating Rocapuldencel - T (AGS-003) - Slideshow
seekingalpha.com - September 22 at 1:26 PM
globenewswire.com logoArgos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO ... - GlobeNewswire (press release)
globenewswire.com - September 19 at 4:05 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) versus Vericel Corporation (VCEL) Head to Head Contrast
www.americanbankingnews.com - September 17 at 10:48 PM
americanbankingnews.com logoChiasma (CHMA) and Argos Therapeutics (ARGS) Critical Contrast
www.americanbankingnews.com - September 15 at 6:28 PM
globenewswire.com logoArgos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - September 13 at 5:11 PM
streetinsider.com logoArgos Therapeutics (ARGS) Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO - StreetInsider.com
www.streetinsider.com - September 12 at 4:16 PM
finance.yahoo.com logoArgos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
finance.yahoo.com - September 12 at 4:16 PM
finance.yahoo.com logoETFs with exposure to Argos Therapeutics, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 1:57 AM
streetinsider.com logoArgos Therapeutics (ARGS) Reports First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir
www.streetinsider.com - September 6 at 8:59 PM
streetinsider.com logoArgos Therapeutics (ARGS) Reports First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir - StreetInsider.com
www.streetinsider.com - September 6 at 3:58 PM
finance.yahoo.com logoETFs with exposure to Argos Therapeutics, Inc. : August 31, 2017
finance.yahoo.com - September 1 at 1:01 AM
americanbankingnews.com logoHead-To-Head Comparison: Argos Therapeutics (ARGS) vs. Transition Therapeutics (TTHI)
www.americanbankingnews.com - August 24 at 4:08 AM
americanbankingnews.com logoContrasting Strongbridge Biopharma PLC (SBBP) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - August 21 at 4:24 PM
globenewswire.com logoArgos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - August 21 at 4:08 PM
americanbankingnews.com logoArgos Therapeutics, Inc. (ARGS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 14 at 4:55 PM
americanbankingnews.com logoComparing BioMarin Pharmaceutical (BMRN) and Argos Therapeutics (NASDAQ:ARGS)
www.americanbankingnews.com - August 10 at 10:20 PM
americanbankingnews.com logoArgos Therapeutics, Inc. (ARGS) Releases Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
globenewswire.com logoArgos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights - GlobeNewswire (press release)
globenewswire.com - August 9 at 9:14 PM
finance.yahoo.com logoArgos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 9 at 9:14 PM
finance.yahoo.com logoArgos Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 9:14 PM
americanbankingnews.com logoArgos Therapeutics, Inc. (ARGS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 5:26 PM
finance.yahoo.com logoArgos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing
finance.yahoo.com - June 22 at 12:09 PM
streetinsider.com logoArgos Therapeutics (ARGS) Announces $6M Secured Convertible Note Financing - StreetInsider.com
www.streetinsider.com - June 18 at 11:53 AM
streetinsider.com logoArgos Therapeutics (ARGS) Announces $6M Secured Convertible Note Financing
www.streetinsider.com - June 17 at 3:41 PM
prnewswire.com logoTechnical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ - PR Newswire (press release)
www.prnewswire.com - June 14 at 3:43 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 6 at 10:46 PM
finance.yahoo.com logoETFs with exposure to Argos Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:23 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:28 PM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logoArgos Therapeutics Inc (ARGS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 10:58 PM
streetinsider.com logoArgos Therapeutics (ARGS) Offers Update on ADAPT Trial Following Meeting with FDA
www.streetinsider.com - May 11 at 4:02 PM
streetinsider.com logoArgos Therapeutics (ARGS) Offers Update on ADAPT Trial Following Meeting with FDA - StreetInsider.com
www.streetinsider.com - May 10 at 8:51 PM
globenewswire.com logoArgos Provides Update on its ADAPT Trial Following Meeting with FDA - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:13 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
finance.yahoo.com - May 9 at 8:38 PM
finance.yahoo.com logoArgos Therapeutics faces threat of delisting
finance.yahoo.com - May 5 at 3:38 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receives Media Impact Rating of 0.30
www.americanbankingnews.com - May 3 at 7:24 PM
americanbankingnews.com logoZacks Investment Research Upgrades Argos Therapeutics Inc (ARGS) to "Buy"
www.americanbankingnews.com - May 2 at 7:16 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receives Daily Media Impact Score of -0.10
www.americanbankingnews.com - April 29 at 10:52 AM
americanbankingnews.com logoArgos Therapeutics (ARGS) Receiving Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 2:54 PM
finance.yahoo.com logoRobbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action - Yahoo Finance
finance.yahoo.com - April 24 at 3:38 PM
finance.yahoo.com logoRobbins Arroyo LLP Reminds Investors of Lead Plaintiff Deadline in Argos Therapeutics, Inc. (ARGS) Class Action
finance.yahoo.com - April 24 at 3:38 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Getting Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 23 at 10:17 AM
businesswire.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos ...
www.businesswire.com - April 22 at 10:31 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Argos Therapeutics Inc's Q1 2017 Earnings (ARGS)
www.americanbankingnews.com - April 21 at 8:57 AM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in Argos Therapeutics, Inc. to Contact the Firm
finance.yahoo.com - April 20 at 8:42 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 20 at 2:40 PM
seekingalpha.com logoArgos Therapeutics (ARGS) Presents Interim Analysis Of ADAPT Trial - Slideshow
seekingalpha.com - April 20 at 1:43 AM
benzinga.com logoMid-Day Market Update: Dow Turns Negative; Argos Therapeutics Shares Spike Higher - Benzinga
www.benzinga.com - April 19 at 3:40 PM
streetinsider.com logoArgos Therapeutics (ARGS) Announces Interim Results of ADAPT Trial; to Continue Trial - StreetInsider.com
www.streetinsider.com - April 19 at 3:40 PM
nasdaq.com logoARGS Gets New Lease Of Life, RARE Surges On Study Results, NVLS Abuzz
www.nasdaq.com - April 19 at 8:46 AM

Social

Chart

Argos Therapeutics (ARGS) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff